Product Details

Liability demands putting sites at risk

Liability. Indemnification. Risk. These have emerged as the new four-letter words of clinical trials.

As sites increasingly are being asked to indemnify drug sponsors in order to participate in a clinical study, liability issues have moved to the forefront. Yet since most standard medical or professional liability insurance policies won’t cover these types of agreements, investigators could end up paying damages and costs from indemnification claims out of their own pockets.

New recruitment tools abound, but results remain unclear

Patient recruitment—one of the most challenging and expensive aspects of the clinical research process—has undergone myriad changes over the years.

Eye On Daiichi Sankyo

Daiichi Sankyo’s self-stated mission is “to create innovative pharmaceuticals that improve the health and quality of life for people around the world and make them available as soon as possible.” To meet this challenge, it relies on its investigators’ creativity, respect for human life and technical expertise. R&D operations are headquartered in Japan and Germany, and products in the pipeline are tested at its facilities around the world.

Also in this issue:

• Surviving budget season
• Rethinking global clinical trials
• Industry Briefs
• The Pulse on Recruitment
• TrialWatch
• New Study Launches